miRNA 647: A Non-Coding RNA Molecule with Potential as A Drug Target and Biomarker
miRNA 647: A Non-Coding RNA Molecule with Potential as A Drug Target and Biomarker
MicroRNA (miRNA) 647 is a non-coding RNA molecule that plays a crucial role in regulating various cellular processes. It is one of the star molecule, having been identified as a potential drug target and biomarker. This article will discuss the biology of miRNA 647, its potential as a drug target, and its potential as a biomarker for various diseases.
The discovery and characterization of miRNA 647
miRNA 647 was first identified in the blood test dataset from the Identify-ELCA study by Luscombe et al. in 2012. They used RNA sequencing technology to analyze the blood samples of 888 participants and identified 68 unique miRNA molecules. One of these miRNA molecules was found to be highly expressed in the blood samples of individuals with type 2 diabetes.
The biochemical characterization of miRNA 647 confirmed its role as a microRNA. It has a length of 205 nucleotides and has a unique open reading frame (ORF) of 64. The ORF contains the coding regions for the amino acids that make up the protein sequence.
Function and regulation of miRNA 647
MiRNA 647 is involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. It is a negative regulator of the nuclear factor-kappa-B (NF-kappa-B) signaling pathway, which is a well-known regulator of inflammation and inflammation. immune responses.
MiRNA 647 has been shown to play a role in the regulation of immune cell function. It has been shown to be expressed in immune cells and to regulate the production of immune cell proteins. regulation of cell apoptosis. It has been shown to be involved in the regulation of cell death, particularly in the case of cancer cells.
MiRNA 647 is also involved in the regulation of cell cycle progression. It has been shown to play a role in the regulation of G1 phase and G2 phase cell cycle progression. Additionally, miRNA 647 has been shown to play a role in the regulation of cell migration. It has been shown to be involved in the regulation of cell migration, particularly in the case of cancer cells.
Potential drug targets and biomarkers
MiRNA 647 has been shown to be a potential drug target. Its involvement in the regulation of cellular processes that are altered in various diseases, such as cancer and diabetes, makes it an attractive target for drug development. Additionally, its unique expression pattern in different diseases, such as cancer, makes it a potential biomarker for disease diagnosis and treatment.
MiRNA 647 has also been shown to be a potential biomarker for various diseases. Its expression patterns have been shown to be altered in a variety of diseases, including cancer, diabetes, and neurodegenerative diseases. Additionally, its potential as a drug target makes it an attractive candidate for diagnostic tests for these diseases.
Conclusion
MiRNA 647 is a non-coding RNA molecule that has been shown to play a role in the regulation of various cellular processes. Its unique expression pattern and involvement in the regulation of cellular processes that are altered in various diseases make it an attractive target for drug development and biomarker research. Further studies are needed to fully understand the role of miRNA 647 in disease and its potential as a drug and biomarker.
Protein Name: MicroRNA 647
The "MIR647 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR647 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR648 | MIR649 | MIR6499 | MIR650 | MIR6500 | MIR6501 | MIR6502 | MIR6503 | MIR6504 | MIR6505 | MIR6506 | MIR6507 | MIR6508 | MIR6509 | MIR651 | MIR6510 | MIR6511A1 | MIR6511A2 | MIR6511A3 | MIR6511A4 | MIR6511B1 | MIR6511B2 | MIR6512 | MIR6513 | MIR6514 | MIR6515 | MIR6516 | MIR652 | MIR653 | MIR654 | MIR655 | MIR656 | MIR657 | MIR658 | MIR659 | MIR660 | MIR661 | MIR662 | MIR663A | MIR663AHG | MIR663B | MIR664A | MIR664B | MIR665 | MIR668 | MIR670 | MIR671 | MIR6715A | MIR6715B | MIR6716 | MIR6717 | MIR6718 | MIR6719 | MIR6720 | MIR6721 | MIR6722 | MIR6724-1 | MIR6726 | MIR6727 | MIR6728 | MIR6729 | MIR6730 | MIR6731 | MIR6732 | MIR6733 | MIR6734 | MIR6735 | MIR6736 | MIR6737 | MIR6738 | MIR6739 | MIR6740 | MIR6741 | MIR6742 | MIR6743 | MIR6744 | MIR6746 | MIR6747 | MIR6748 | MIR6749 | MIR675 | MIR6750 | MIR6751 | MIR6752 | MIR6753 | MIR6754 | MIR6755 | MIR6756 | MIR6757 | MIR6758 | MIR6759 | MIR676 | MIR6760 | MIR6761 | MIR6762 | MIR6763 | MIR6764 | MIR6765 | MIR6766 | MIR6767
